Articles tagged with Cancer Patients
A recent study found that most elderly women with non-metastatic breast cancer comply with hormone therapy recommendations. However, non-white women were more likely to discontinue treatment, highlighting a need for targeted interventions.
Researchers found that combining low doses of bortezomib with an oncolytic virus significantly improves the ability to kill cancer cells. The combination treatment suppressed tumor growth by 92% in a glioma model and improved survival rates, offering a novel therapeutic strategy for solid tumors.
New research links low blood cholesterol to more advanced tumor stages and reduced cancer survival rates in kidney cancer patients. High cholesterol levels are associated with a lower risk of death from the disease, suggesting a potential new prognostic tool for monitoring patient outcomes.
The Phase 2B clinical trial of CRS-207 and GVAX Pancreas vaccines aims to improve treatment outcomes for patients with advanced pancreatic cancer. The combination regimen shows promise in improving survival rates, with no serious treatment-related adverse side effects.
Researchers at UNC have found that Set2 plays a crucial role in DNA repair, which can lead to the development of cancer cells if impaired. The discovery offers insights into creating more targeted therapies for various forms of cancer.
Researchers found that early palliative support services significantly reduced depression and feelings of overwhelm among family caregivers, improving overall quality of life. The study suggests that timely intervention can better equip caregivers to cope with the demands of caring for patients with advanced cancer.
Researchers found that fasting can replenish stem cells in the blood, combating chemotherapy-induced and aging-related changes in immune cell function. Fasting has also been shown to rejuvenate the immune system of old mice and protect against white blood cell loss in human patients.
A new drug called MM-398 has shown a significant overall survival rate in patients with advanced pancreatic cancer when given in combination with 5-flourouracil and leucovorin. The study achieved an overall survival of 6.1 months, a 1.9 month improvement over the control arm.
A recent study suggests that expanded health coverage under the Affordable Care Act (ACA) may lead to better cancer outcomes for young adults. The study found that patients with insurance coverage were more likely to receive definitive therapy and had a higher survival rate compared to uninsured individuals.
The challenges in cancer molecular testing require effective communication between oncologists and pathologists. Close communication, systems approaches, and new institutional protocols can help ensure efficient testing and optimal patient outcomes.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
A non-invasive breath test has been developed to detect lung cancer by analyzing volatile organic compounds in exhaled breath. The device can distinguish between patients with lung cancer and chronic obstructive pulmonary disease (COPD), as well as define the stage of any present cancer.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
Research identifies new ways to ease cancer therapy effects and enhance patient well-being, from fertility preservation techniques to earlier palliative care. Studies show improved survival rates and reduced side effects for certain treatments.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The American Society for Clinical Oncology has released new clinical guidelines for cancer-related fatigue, developed in collaboration with Moffitt Cancer Center. The guidelines recommend regular screening and treatment of fatigue in cancer patients after treatment, as well as addressing other contributing factors such as depression, p...
Researchers at Fox Chase Cancer Center halted a trial after 23% of patients experienced severe cardiovascular events while receiving a chemotherapy regimen. The study aimed to investigate the effectiveness and safety of gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
Researchers at Fox Chase Cancer Center found that genetic mutations in three specific genes can predict which bladder cancer patients will benefit from early chemotherapy. Patients with these mutations are more likely to respond to treatment and have a higher chance of being cancer-free after surgery.
Chronic kidney disease is associated with a higher risk of developing renal and urothelial cancers. A recent study found that patients with reduced glomerular filtration rates were more likely to develop these types of cancer, particularly those with severe chronic kidney disease.
A retrospective study of over 1.2 million adults found that reduced glomerular filtration rate is an independent risk factor for renal and urothelial cancer, but not other types of cancer. Lower GFR levels were associated with increased rates of incident renal cancer and urothelial cancer.
A new study has discovered how ibrutinib resistance develops in CLL patients, identifying key gene mutations that weaken the drug's ability to bind with Bruton's tyrosine kinase. This understanding is crucial for developing effective alternative treatments for patients who develop resistance.
The USPSTF recommends screening for hepatitis B virus (HBV) in nonpregnant high-risk adolescents and adults, as well as postnatal immunoprophylaxis to prevent maternal transmission. Studies have shown that these interventions can reduce mortality and hospital readmissions related to heart failure.
Researchers discovered uric acid's role as a major intracellular antioxidant that prevents oxidative stress and its impact on cancer and aging. The p53-GLUT9 pathway is a mechanism to prevent ROS accumulation, which causes cell damage.
A recent study highlights the challenges faced by refugees from Iraq and Syria in accessing affordable cancer treatment, with host countries struggling to find the money and medicine. Innovative financing schemes are needed to improve access to quality care for these patients.
Research suggests that patients with polycystic kidney disease (PKD) who undergo a kidney transplant may be less likely to develop cancer compared to those without PKD. The study found that PKD patients were 16% less likely to develop cancer than others who received a kidney transplant, and their overall cancer risk was 48% lower than ...
Researchers used computer simulations to identify most effective drugs for brain cancer, considering genomic signatures and predicted sensitivities. The approach may help personalize therapies for cancer patients, selectively testing effective drugs while reducing exposure to toxic ones.
A systematic review compared the efficacy and safety of radiofrequency ablation (RFA) and complete endoscopic resection (EMR) for dysplastic Barrett's esophagus. Both treatments were found to be effective in short-term treatment, but RFA had lower short-term adverse event rates. Long-term esophageal strictures were more common with EMR.
A study of 2,290 women with breast cancer found that while many consider or undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the other breast, most do not have a clinically significant risk. The procedure is often associated with genetic testing, family history, and higher education.
Circadian rhythm disruption during chemotherapy worsens its side effects, including fatigue and body weight loss. Researchers suggest personalising chronotherapy delivery to improve clinical tolerability and potentially boost treatment effectiveness.
The Gordon Sondland and Katherine Durant Foundation has donated $1 million to the Oregon Health & Science University's Knight Cancer Institute to establish an annual research conference, drawing top thought leaders in cancer treatment. The conference aims to accelerate breakthroughs in early detection and treatment.
Researchers found distinct profiles of bacteria in saliva that may indicate early-stage pancreatic cancer diagnosis. High levels of Leptotrichia and Campylobacter were detected in patients with pancreatic cancer compared to healthy controls.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
A team of scientists has identified cancer stem cells in patients with myelodysplastic syndromes, a malignant blood condition that frequently develops into acute myeloid leukemia. The study provides conclusive evidence for the existence of cancer stem cells and suggests that targeting these cells could lead to effective treatment.
A new chemotherapy regimen administered before surgery and chemoradiation improves tolerance to treatment in most rectal cancer patients. The study found that over 90% of patients were able to complete a full course of standard treatment, with many experiencing a significant reduction in symptoms.
A new study from Penn Medicine's Abramson Cancer Center found that inappropriate cancer patient demands are uncommon and rarely lead to unnecessary tests and treatments. Most clinicians believe most patient requests are appropriate and incorporated into suitable treatment plans.
A 1993 trial found no survival advantage in second look surgery for colorectal cancer patients with high CEA levels. The new analysis confirms this finding, despite methodological changes over the past two decades.
A recent study published in Pediatrics suggests that children exposed to a parent's nicotine-dependent smoking are at a higher risk of becoming heavy smokers themselves. Parental smoking cessation early on is crucial to prevent habitual smoking in the next generation.
Researchers at Ohio State University have developed a novel strategy for treating multiple myeloma by genetically modifying T lymphocytes to target the CS1 molecule on myeloma cells. The modified cells were shown to efficiently destroy human multiple myeloma cells in laboratory studies and animal models.
A nationwide dataset analysis found that black women are 1.84 times more likely to be diagnosed with triple-negative breast cancer, a subtype with poorer prognosis. Asian/Pacific Islander women were also more likely to be diagnosed with HER2-overexpressing breast cancer.
Researchers identified potentially actionable mutations in cancers of the appendix using next-generation DNA sequencing. KRAS and GNAS mutations were found to be common alterations in both low-grade appendiceal mucinous neoplasm (LAMN) and adenocarcinoma tumors.
A Phase I study of an experimental antibody produced at St. Jude Children's Research Hospital found tumors shrank or disappeared in some patients with advanced neuroblastoma, and disease progression was temporarily halted in 15 children.
Researchers at Wake Forest Baptist Medical Center have successfully treated patients with recurrent lung cancers using a second course of radiation therapy, achieving a cure rate of over 70%. The innovative treatment approach uses precise targeting and high doses to knock the cancer back, offering new hope for these patients.
A Kaiser Permanente study found that radiation treatment significantly reduced the risk of Merkel cell carcinoma recurrence, with no impact on survival rates. The study's results also showed associations between immunosuppression and advanced tumors, as well as lymph node evaluation, and worse survival outcomes.
The GW Cancer Institute has received a $100,000 grant from the Avon Foundation to support a patient navigator. The patient navigator will help remove barriers and coordinate access to care for over 1,000 patients with breast cancer in the Washington D.C. area.
Researchers used molecular tumor boards to evaluate 34 patients with advanced cancer, identifying 74 genes and 123 aberrations involved in cancer growth. The approach showed promise in tailoring personalized treatment plans for patients who have exhausted standard therapies.
A review of 47 studies involving over 15,000 patients found that liver cancer screening using ultrasound scans and blood tests significantly improved three-year survival rates for people with cirrhosis. Cirrhosis patients who received screening were more likely to receive curative treatment rather than palliative care.
A phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment relieves pain and improves function for most patients with bone metastases. Patients responded well to treatment, with 64 percent experiencing either no pain or a significant reduction in their pain within several days of treatment.
A study published in Journal of Clinical Oncology found low transmission rates among long-term partners of patients with oral HPV infection. The prevalence of oral HPV among partners was comparable to the general population, confirming that couples do not need to change their intimacy due to cancer diagnosis.
Dartmouth researchers found tweens who participate in coached team sports are less likely to try smoking. Participating in other clubs was also associated with lower risk of trying drinking.
Microfluidic technology reveals potential biomarker for early pancreatic cancer, capturing circulating pancreas cells in 33% of patients with early lesions. The detection may indicate an early sign of cancer, and a clinical trial is underway to predict patient risk.
Researchers discovered that tumors with specific immunogenic mutations can activate a protective immune response, leading to higher overall survival rates. The study's findings support personalized cancer immunotherapy approaches and the use of tumor-specific mutations in creating targeted vaccines.
A study found that vitamin D levels are linked to better outcomes in several types of cancer. Patients with higher vitamin D levels tend to have better survival rates and remain in remission longer than those who are deficient.
Dartmouth has been awarded a grant to serve as a Lead Academic Participating Site in the National Clinical Trials Network, aiming to streamline clinical trial operations and improve access to new treatments. The network's goals include faster trial design, optimal use of scientific innovations, and expanded patient participation.
Researchers discovered that PTEN mutations contribute to tumorigenesis by regulating different aspects of PTEN biology, and targeting Akt's pathway may be an effective treatment strategy for patients with PTEN mutations. The findings suggest that personalized cancer medicine is urgently needed.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline detailing the use of adjuvant radiation therapy in treating endometrial cancer. The guideline recommends postoperative external beam radiation for patients with early-stage disease, and vaginal cuff brachytherapy for those at high risk of vaginal recurrence.
Researchers at Ohio State University found that microRNA-3151 promotes AML-cell growth and survival by blocking tumor-suppressor gene TP53. High expression of miR-3151 is associated with a bad prognosis, while inhibition with the drug bortezomib offers a possible therapy.
Celldex Therapeutics' Phase 1 study of CDX-1401 demonstrates robust antibody and T cell responses, with evidence of clinical benefit in patients with very advanced cancers. The vaccine induces durable humoral and cellular immunity, with stable disease observed in a significant proportion of patients.
A new blood test, cMethDNA assay, has been developed to detect advanced breast cancer and monitor its response to treatment with high accuracy. The test detected cancer DNA in the blood of patients with metastatic breast cancers up to 95% of the time, making it a promising tool for early detection and treatment monitoring.
Clinical trials show chemotherapy before surgery improves muscle-invasive bladder cancer survival. Chemotherapy after surgery also increases survival rates, with a significant improvement over time.
A new study finds that microRNA 135b drives the growth of bowel cancers and is a vital 'worker' for several important cancer genes. Testing levels of this molecule could identify patients with aggressive disease, while drugs targeting it may prevent tumour growth and reduce resistance.